Repligen Co. (NASDAQ:RGEN) Position Increased by Retirement Systems of Alabama

Retirement Systems of Alabama lifted its holdings in Repligen Co. (NASDAQ:RGEN) by 0.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 65,032 shares of the biotechnology company’s stock after buying an additional 288 shares during the quarter. Retirement Systems of Alabama owned approximately 0.12% of Repligen worth $11,693,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of RGEN. Alliance Wealth Advisors LLC UT lifted its position in Repligen by 4.9% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 2,460 shares of the biotechnology company’s stock valued at $442,000 after purchasing an additional 114 shares during the last quarter. Truist Financial Corp grew its holdings in Repligen by 14.5% in the 4th quarter. Truist Financial Corp now owns 4,250 shares of the biotechnology company’s stock worth $764,000 after buying an additional 538 shares in the last quarter. Watershed Asset Management L.L.C. increased its position in Repligen by 27.1% in the 4th quarter. Watershed Asset Management L.L.C. now owns 8,900 shares of the biotechnology company’s stock valued at $1,600,000 after acquiring an additional 1,900 shares during the period. Parkside Financial Bank & Trust raised its stake in Repligen by 15.9% during the 4th quarter. Parkside Financial Bank & Trust now owns 859 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 118 shares in the last quarter. Finally, Foundry Partners LLC acquired a new position in Repligen during the 4th quarter worth $204,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Down 3.6 %

Shares of NASDAQ:RGEN opened at $158.36 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. The stock has a market capitalization of $8.84 billion, a price-to-earnings ratio of 219.95, a PEG ratio of 5.38 and a beta of 1.03. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a 50 day moving average price of $181.94 and a 200 day moving average price of $173.85.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. During the same period in the previous year, the firm posted $0.68 EPS. The company’s quarterly revenue was down 16.6% on a year-over-year basis. On average, research analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Activity at Repligen

In other news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Stifel Nicolaus raised their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. KeyCorp boosted their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.